EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 12

Safflower Carthamus tinctorius L.

Also called: safflower oil, safflower yellow, Carthamus tinctorius

Safflower (Carthamus tinctorius) is a crop native from central and eastern Türkiye to Iran, cultivated mainly for its seed, which yields an edible oil. Its flowers and seeds are used in traditional herbal medicine in China, Korea and Japan.

Category
Botanical
Part used
Seed oil (food-oil studies) and flower (traditional medicine; source of safflower yellow)
Strongest evidence
B Some positive trials
Native range
Native range (POWO): Central & E. Türkiye to Iran
Reviewed
2026-10-30

Class 1 Well studied in people. A 2014 systematic review included 7 RCTs (762 participants) of safflower yellow, a flower-pigment preparation, for acute ischemic stroke; several trial reports it cites describe safflower yellow injection, which is not oral supplement use. Seed-oil trials are not part of this count. [6]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied2 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Safflower does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Safflower, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Seed oil: LDL and total cholesterol compared with other oils and fatsBA 2018 network meta-analysis of 54 randomized trials comparing oils and solid fats ranked safflower oil highest for lowering LDL cholesterol (SUCRA 82%) and total cholesterol (SUCRA 90%). [4]
Seed oil replacing saturated fat after a coronary event (Sydney Diet Heart Study)XIn a randomized trial of 458 men, replacing saturated fats with safflower oil and safflower-oil margarine led to higher death rates from all causes, cardiovascular disease and coronary heart disease than controls. [3]
Seed oil: blood sugar in obese postmenopausal women with type 2 diabetesCIn one double-masked crossover RCT (55 enrolled, 35 completed), 8 g/day safflower oil for 16 weeks lowered HbA1c and raised HDL cholesterol. [5]
Safflower yellow (a flower pigment preparation, injected in cited trials): acute ischemic strokeBA 2014 systematic review of 7 RCTs (762 participants; cited trial reports describe injections, not oral use) found a higher neurological improvement rate than control; none of the trials was of high methodological quality. [6]

Main constituents: Flower: carthamin and safflower yellow are the main constituents; hydroxysafflor yellow A, safflor yellow A and luteolin are also reported [1]; Flavonoids and alkaloids, especially the quinochalcone C-glycoside hydroxysafflor yellow A, N-(p-coumaroyl)serotonin and N-feruloylserotonin, are responsible for most pharmacological activities [2]; Seed oil: omega-6 linoleic acid (the safflower oil used in the Sydney Diet Heart Study) [3]; High-oleic safflower oil: a type containing at least 70% oleic acid, named in FDA's qualified health claim [9]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • 8 g of safflower oil daily for 16 weeks in the diabetes crossover trial. [5]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Cancer evaluations (IARC, NTP)
    1 found

    Each names the exact material tested, which may differ from a supplement.

    Details and sources
  • FDA new dietary ingredient notifications
    2 on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    None found

    No published information found in the sources checked.

    Details and sources
  • Sydney Diet Heart Study: men with a recent coronary event who replaced saturated fats with safflower oil had higher rates of death than controls; an updated meta-analysis of linoleic acid trials showed no evidence of cardiovascular benefit. [3]
  • NTP TR-426 (1994): in 2-year gavage studies in male rats (2.5 to 10 mL/kg), safflower oil, like corn oil and tricaprylin, caused hyperplasia and adenoma of the exocrine pancreas. [7]
  • Occupational asthma from dried flowers of safflower and yarrow has been reported. [8]
  • In the stroke review of safflower yellow (injected in cited trials), only four trials reported adverse events; skin rash was seen in the treatment group of one trial, and no deaths were reported. [6]
Quality

Identity, quality and standardization

  • FDA's qualified health claim for oleic acid oils covers high-oleic safflower oil only when the oil contains at least 70% oleic acid per serving. [9]
Regulation

Regulatory status

  • US: FDA's published NDI notification list has 2 entries naming safflower (Carthamus tinctorius): a GLA safflower oil derived from the seed (NDI 609 submitted 2009-08-31) and conjugated linoleic acid derived from the oil (NDI 650 submitted 2010-04-13). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [10]
  • US: FDA's qualified health claim for oleic acid (review completed November 19, 2018) covers high-oleic safflower oil; the claim says supportive but not conclusive evidence suggests about 1½ tablespoons (20 grams) daily of such oils, replacing fats higher in saturated fat, may reduce the risk of coronary heart disease. [9]
  • US: under DSHEA, FDA does not have the authority to approve dietary supplements before they are marketed; firms are responsible for ensuring their products are not adulterated or misbranded. [11]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Flower: hydroxysafflor yellow A (a quinochalcone C-glycoside), with N-(p-coumaroyl)serotonin and N-feruloylserotonin, named as responsible for most pharmacological activities Flavonoids (quinochalcone C-glycoside) and alkaloids [P1]
  • Flower: carthamin and safflower yellow, the main flower constituents Flower pigments (chemical class not stated by the cited source) [P2]
  • Seed oil: omega-6 linoleic acid Fatty acids [P3]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • FDA's published NDI notification list has 2 entries naming safflower (Carthamus tinctorius): a GLA safflower oil derived from the seed (NDI 609 submitted 2009-08-31) and conjugated linoleic acid derived from the oil (NDI 650 submitted 2010-04-13). Each notification covers one firm's specific ingredient and conditions of use; the list does not state FDA's response. [P4]
  • FDA's qualified health claim for oleic acid and coronary heart disease (review completed November 19, 2018) names high-oleic safflower oil among covered oils, which must contain at least 70% oleic acid per serving. [P5]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • Safflower oil (as a gavage vehicle), NTP TR-426 (April 1994): in 2-year studies in male F344/N rats at 2.5, 5 or 10 mL/kg, corn oil, safflower oil and tricaprylin each caused hyperplasia and adenoma of the exocrine pancreas; with safflower oil, adenoma rose from 1/50 in untreated controls to 28/50 at 10 mL/kg. [P6]
  • No IARC evaluation of safflower (Carthamus tinctorius) or safflower oil was found (IARC Monographs list of classifications, list data last updated 2026-07-23, checked 2026-10-29). [P7]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • No published information found in the sources checked.

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity test or examination of each dietary-ingredient component — US cGMP rule for dietary supplements: at least one appropriate test or examination must verify the identity of any component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)); exemption only through a petition FDA grants (111.75(a)(1)(ii)). [P8]
  • Fatty acid profile (oleic acid content) for high-oleic safflower oil — FDA's qualified health claim applies only to oils containing at least 70% oleic acid per serving. [P5]

Supply and conservation

  • GBIF species API returns IUCN Red List category Not Evaluated (NE) for Carthamus tinctorius, retrieved 2026-10-29. [P9]
  • Cultivated mainly for its seed, which is used as edible oil. [P2]

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • No published information found in the sources checked.

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Zhang LL, Tian K, Tang ZH, et al. Phytochemistry and pharmacology of Carthamus tinctorius L. Am J Chin Med 2016;44(2):197-226 (PMID 27080938), 2016. pubmed.ncbi.nlm.nih.gov
  2. Asgarpanah J, Kazemivash N. Phytochemistry, pharmacology and medicinal properties of Carthamus tinctorius L. Chin J Integr Med 2013;19(2):153-9 (PMID 23371463), 2013-02. pubmed.ncbi.nlm.nih.gov
  3. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ 2013;346:e8707 (PMID 23386268), 2013-02-04. pubmed.ncbi.nlm.nih.gov
  4. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  5. FDA. FDA Completes Review of Qualified Health Claim Petition for Oleic Acid and the Risk of Coronary Heart Disease (November 19, 2018), 2018-11-19. fda.gov
  6. National Toxicology Program. TR-426: Comparative Toxicology Studies of Corn Oil, Safflower Oil, and Tricaprylin in Male F344/N Rats as Vehicles for Gavage (April 1994), 1994-04. ntp.niehs.nih.gov
  7. IARC Monographs. List of Classifications (list data last updated 2026-07-23; retrieved October 29, 2026), 2026-10-29. monographs.iarc.who.int
  8. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of October 23, 2026), 2026-10-23. ecfr.gov
  9. GBIF species API: IUCN Red List category for Carthamus tinctorius L. (usageKey 3138327), 2026-10-29. api.gbif.org
Sources

Sources

  1. Asgarpanah J, Kazemivash N. Phytochemistry, pharmacology and medicinal properties of Carthamus tinctorius L. Chin J Integr Med 2013;19(2):153-9 (PMID 23371463), 2013-02. pubmed.ncbi.nlm.nih.gov
  2. Zhang LL, Tian K, Tang ZH, et al. Phytochemistry and pharmacology of Carthamus tinctorius L. Am J Chin Med 2016;44(2):197-226 (PMID 27080938), 2016. pubmed.ncbi.nlm.nih.gov
  3. Ramsden CE, Zamora D, Leelarthaepin B, et al. Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis. BMJ 2013;346:e8707 (PMID 23386268), 2013-02-04. pubmed.ncbi.nlm.nih.gov
  4. Schwingshackl L, Bogensberger B, Benčič A, et al. Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. J Lipid Res 2018;59(9):1771-1782 (PMID 30006369), 2018-09. pubmed.ncbi.nlm.nih.gov
  5. Asp ML, Collene AL, Norris LE, et al. Time-dependent effects of safflower oil to improve glycemia, inflammation and blood lipids in obese, post-menopausal women with type 2 diabetes: a randomized, double-masked, crossover study. Clin Nutr 2011;30(4):443-9 (PMID 21295383), 2011-08. pubmed.ncbi.nlm.nih.gov
  6. Fan S, Lin N, Shan G, Zuo P, Cui L. Safflower yellow for acute ischemic stroke: a systematic review of randomized controlled trials. Complement Ther Med 2014;22(2):354-61 (PMID 24731908), 2014-04. pubmed.ncbi.nlm.nih.gov
  7. National Toxicology Program. TR-426: Comparative Toxicology Studies of Corn Oil, Safflower Oil, and Tricaprylin in Male F344/N Rats as Vehicles for Gavage (April 1994), 1994-04. ntp.niehs.nih.gov
  8. Compes E, Bartolomé B, Fernández-Nieto M, Sastre J, Cuesta J. Occupational asthma from dried flowers of Carthamus tinctorious (safflower) and Achillea millefolium (yarrow). Allergy 2006;61(10):1239-40 (PMID 16942580), 2006-10. pubmed.ncbi.nlm.nih.gov
  9. FDA. FDA Completes Review of Qualified Health Claim Petition for Oleic Acid and the Risk of Coronary Heart Disease (November 19, 2018), 2018-11-19. fda.gov
  10. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  11. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
  12. Plants of the World Online (Royal Botanic Gardens, Kew). Carthamus tinctorius L. (retrieved October 29, 2026), 2026-10-29. powo.science.kew.org
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.